When it comes to high-throughput screening, you probably think of research at a large pharmaceutical company. Pharmas spend countless hours and untold sums of money searching for drugs and drug targets, refining the process, and searching some more. At the same time, academia tends to ignore the further-downstream possibilities of high-throughput screening, focusing on more basic biological interests. But not the University of Kansas. The school is carving out a place for itself on the academic side of drug discovery, particularly to fill unmet clinical needs such as rare cancers.